Histone variants: Nuclear function and disease

Current Opinion in Genetics and Development

Volumn 37, Issue , 2016, Pages 82-89

  Zink, Lisa Maria ^a   Hake, Sandra B ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Munich Center for Integrated Protein Science   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE PROTEIN A; HISTONE; HISTONE H2A; HISTONE H2A.1.1; HISTONE H2A.1.2; HISTONE H2A.2; HISTONE H2A.Z.1; HISTONE H2A.Z.2.1; HISTONE H2A.Z.2.2; HISTONE H3.3; UNCLASSIFIED DRUG; CHROMATIN; DNA;

BLADDER CANCER; BREAST CANCER; CANCER PROGNOSIS; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CHONDROBLASTOMA; COLON CANCER; COLORECTAL CANCER; ENDOMETRIUM CANCER; GENE ACTIVITY; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC STABILITY; GIANT CELL TUMOR; GLIOMA; HUMAN; HUNTINGTON CHOREA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; METASTATIC MELANOMA; MITOSIS INDEX; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PONTINE GLIOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SMALL INTESTINE METASTASIS; TERATOMA; TESTIS CANCER; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; BIOSYNTHESIS; CHROMATIN; CHROMOSOME SEGREGATION; DNA REPAIR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC VARIATION; GENETICS;

CHROMATIN; CHROMOSOME SEGREGATION; DNA; DNA REPAIR; GENE EXPRESSION REGULATION; GENETIC VARIATION; HISTONES; HUMANS; TRANSCRIPTION, GENETIC;

EID: 84955604388     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2015.12.002     Document Type: Review

References (71)

1. Marzluff W.F., Gongidi P., Woods K.R., Jin J., Maltais L.J. The human and mouse replication-dependent histone genes. Genomics 2002, 80:487-498.
2. Bonisch C., Nieratschker S.M., Orfanos N.K., Hake S.B. Chromatin proteomics and epigenetic regulatory circuits. Expert Rev Proteomics 2008, 5:105-119.
3. Elsasser S.J., Noh K.M., Diaz N., Allis C.D., Banaszynski L.A. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. Nature 2015, 522:240-244.
4. Goldberg A.D., Banaszynski L.A., Noh K.M., Lewis P.W., Elsaesser S.J., Stadler S., Dewell S., Law M., Guo X., Li X., et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010, 140:678-691.
5. Voon H.P., Hughes J.R., Rode C., De La Rosa-Velazquez I.A., Jenuwein T., Feil R., Higgs D.R., Gibbons R.J. ATRX plays a key role in maintaining silencing at interstitial heterochromatic loci and imprinted genes. Cell Rep 2015, 11:405-418.
6. Daniel Ricketts M., Frederick B., Hoff H., Tang Y., Schultz D.C., Singh Rai T., Grazia Vizioli M., Adams P.D., Marmorstein R. Ubinuclein-1 confers histone H3.3-specific-binding by the HIRA histone chaperone complex. Nat Commun 2015, 6:7711.
7. Jang C.W., Shibata Y., Starmer J., Yee D., Magnuson T. Histone H3.3 maintains genome integrity during mammalian development. Genes Dev 2015, 29:1377-1392.
8. Nashun B., Hill P.W., Smallwood S.A., Dharmalingam G., Amouroux R., Clark S.J., Sharma V., Ndjetehe E., Pelczar P., Festenstein R.J., et al. Continuous histone replacement by hira is essential for normal transcriptional regulation and de novo DNA methylation during mouse oogenesis. Mol Cell 2015, 60:611-625.
9. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tonjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
10. Lewis P.W., Muller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
11. Khuong-Quang D.A., Buczkowicz P., Rakopoulos P., Liu X.Y., Fontebasso A.M., Bouffet E., Bartels U., Albrecht S., Schwartzentruber J., Letourneau L., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012, 124:439-447.
12. Feng J., Hao S., Pan C., Wang Y., Wu Z., Zhang J., Yan H., Zhang L., Wan H. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol 2015, 11:1626-1632.
13. Behjati S., Tarpey P.S., Presneau N., Scheipl S., Pillay N., Van Loo P., Wedge D.C., Cooke S.L., Gundem G., Davies H., et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013, 45:1479-1482.
14. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., Schulick R.D., Tang L.H., Wolfgang C.L., Choti M.A., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
15. Marinoni I., Kurrer A.S., Vassella E., Dettmer M., Rudolph T., Banz V., Hunger F., Pasquinelli S., Speel E.J., Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014, 146:453-460. e455.
16. Picketts D.J., Higgs D.R., Bachoo S., Blake D.J., Quarrell O.W., Gibbons R.J. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 1996, 5:1899-1907.
17. Gibbons R.J., Pellagatti A., Garrick D., Wood W.G., Malik N., Ayyub H., Langford C., Boultwood J., Wainscoat J.S., Higgs D.R. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet 2003, 34:446-449.
18. Roberts C., Sutherland H.F., Farmer H., Kimber W., Halford S., Carey A., Brickman J.M., Wynshaw-Boris A., Scambler P.J. Targeted mutagenesis of the Hira gene results in gastrulation defects and patterning abnormalities of mesoendodermal derivatives prior to early embryonic lethality. Mol Cell Biol 2002, 22:2318-2328.
19. Rai T.S., Cole J.J., Nelson D.M., Dikovskaya D., Faller W.J., Vizioli M.G., Hewitt R.N., Anannya O., McBryan T., Manoharan I., et al. HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia. Genes Dev 2014, 28:2712-2725.
20. Duarte L.F., Young A.R., Wang Z., Wu H.A., Panda T., Kou Y., Kapoor A., Hasson D., Mills N.R., Ma'ayan A., et al. Histone H3.3 and its proteolytically processed form drive a cellular senescence programme. Nat Commun 2014, 5:5210.
21. Barnhart M.C., Kuich P.H., Stellfox M.E., Ward J.A., Bassett E.A., Black B.E., Foltz D.R. HJURP is a CENP-A chromatin assembly factor sufficient to form a functional de novo kinetochore. J Cell Biol 2011, 194:229-243.
22. Mendiburo M.J., Padeken J., Fulop S., Schepers A., Heun P. Drosophila CENH3 is sufficient for centromere formation. Science 2011, 334:686-690.
23. Howman E.V., Fowler K.J., Newson A.J., Redward S., MacDonald A.C., Kalitsis P., Choo K.H. Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. Proc Natl Acad Sci U S A 2000, 97:1148-1153.
24. Foltz D.R., Jansen L.E., Bailey A.O., Yates J.Rr, Bassett E.A., Wood S., Black B.E., Cleveland D.W. Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell 2009, 137:472-484.
25. Dunleavy E.M., Roche D., Tagami H., Lacoste N., Ray-Gallet D., Nakamura Y., Daigo Y., Nakatani Y., Almouzni-Pettinotti G. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009, 137:485-497.
26. Wu Q., Qian Y.M., Zhao X.L., Wang S.M., Feng X.J., Chen X.F., Zhang S.H. Expression and prognostic significance of centromere protein A in human lung adenocarcinoma. Lung Cancer 2012, 77:407-414.
27. Qiu J.J., Guo J.J., Lv T.J., Jin H.Y., Ding J.X., Feng W.W., Zhang Y., Hua K.Q. Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer. Tumour Biol 2013, 34:2971-2975.
28. McGovern S.L., Qi Y., Pusztai L., Symmans W.F., Buchholz T.A. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res 2012, 14:R72.
29. Lacoste N., Woolfe A., Tachiwana H., Garea A.V., Barth T., Cantaloube S., Kurumizaka H., Imhof A., Almouzni G. Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX. Mol Cell 2014, 53:631-644.
30. Athwal R.K., Walkiewicz M.P., Baek S., Fu S., Bui M., Camps J., Ried T., Sung M.H., Dalal Y. CENP-A nucleosomes localize to transcription factor hotspots and subtelomeric sites in human cancer cells. Epigenetics Chromatin 2015, 8:2.
31. de Tayrac M., Saikali S., Aubry M., Bellaud P., Boniface R., Quillien V., Mosser J. Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas. PLoS One 2013, 8:e73332.
32. Valente V., Serafim R.B., de Oliveira L.C., Adorni F.S., Torrieri R., Tirapelli D.P., Espreafico E.M., Oba-Shinjo S.M., Marie S.K., Paco-Larson M.L., et al. Modulation of HJURP (Holliday Junction-Recognizing Protein) levels is correlated with glioblastoma cells survival. PLoS One 2013, 8:e62200.
33. Kato T., Sato N., Hayama S., Yamabuki T., Ito T., Miyamoto M., Kondo S., Nakamura Y., Daigo Y. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007, 67:8544-8553.
34. Hu Z., Huang G., Sadanandam A., Gu S., Lenburg M.E., Pai M., Bayani N., Blakely E.A., Gray J.W., Mao J.H. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res 2010, 12:R18.
35. Mishra P.K., Au W.C., Choy J.S., Kuich P.H., Baker R.E., Foltz D.R., Basrai M.A. Misregulation of Scm3p/HJURP causes chromosome instability in Saccharomyces cerevisiae and human cells. PLoS Genet 2011, 7:e1002303.
36. Bonisch C., Hake S.B. Histone H2A variants in nucleosomes and chromatin: more or less stable?. Nucleic Acids Res 2012, 40:10719-10741.
37. Monteiro F.L., Baptista T., Amado F., Vitorino R., Jeronimo C., Helguero L.A. Expression and functionality of histone H2A variants in cancer. Oncotarget 2014, 5:3428-3443.
38. Buschbeck M., Di Croce L. Approaching the molecular and physiological function of macroH2A variants. Epigenetics 2010, 5:118-123.
39. Rasmussen T.P., Huang T., Mastrangelo M.A., Loring J., Panning B., Jaenisch R. Messenger RNAs encoding mouse histone macroH2A1 isoforms are expressed at similar levels in male and female cells and result from alternative splicing. Nucleic Acids Res 1999, 27:3685-3689.
40. Ratnakumar K., Duarte L.F., LeRoy G., Hasson D., Smeets D., Vardabasso C., Bonisch C., Zeng T., Xiang B., Zhang D.Y., et al. ATRX-mediated chromatin association of histone variant macroH2A1 regulates alpha-globin expression. Genes Dev 2012, 26:433-438.
41. Costanzi C., Pehrson J.R. Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature 1998, 393:599-601.
42. Gamble M.J., Frizzell K.M., Yang C., Krishnakumar R., Kraus W.L. The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev 2010, 24:21-32.
43. Buschbeck M., Uribesalgo I., Wibowo I., Rue P., Martin D., Gutierrez A., Morey L., Guigo R., Lopez-Schier H., Di Croce L. The histone variant macroH2A is an epigenetic regulator of key developmental genes. Nat Struct Mol Biol 2009, 16:1074-1079.
44. Angelov D., Molla A., Perche P.Y., Hans F., Cote J., Khochbin S., Bouvet P., Dimitrov S. The histone variant macroH2A interferes with transcription factor binding and SWI/SNF nucleosome remodeling. Mol Cell 2003, 11:1033-1041.
45. Creppe C., Janich P., Cantarino N., Noguera M., Valero V., Musulen E., Douet J., Posavec M., Martin-Caballero J., Sumoy L., et al. MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells. Mol Cell Biol 2012, 32:1442-1452.
46. Kustatscher G., Hothorn M., Pugieux C., Scheffzek K., Ladurner A.G. Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol 2005, 12:624-625.
47. Posavec M., Timinszky G., Buschbeck M. Macro domains as metabolite sensors on chromatin. Cell Mol Life Sci 2013, 70:1509-1524.
48. Pehrson J.R., Changolkar L.N., Costanzi C., Leu N.A. Mice without macroH2A histone variants. Mol Cell Biol 2014, 34:4523-4533.
49. Kapoor A., Goldberg M.S., Cumberland L.K., Ratnakumar K., Segura M.F., Emanuel P.O., Menendez S., Vardabasso C., Leroy G., Vidal C.I., et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010, 468:1105-1109.
50. Sporn J.C., Jung B. Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol 2012, 180:2516-2526.
51. Sporn J.C., Kustatscher G., Hothorn T., Collado M., Serrano M., Muley T., Schnabel P., Ladurner A.G. Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 2009, 28:3423-3428.
52. Novikov L., Park J.W., Chen H., Klerman H., Jalloh A.S., Gamble M.J. QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol Cell Biol 2011, 31:4244-4255.
53. Dardenne E., Pierredon S., Driouch K., Gratadau L., Lacroix-triki M., Espinoza M.P., Zonta E., Germann S., Mortada H., Villemin J.P., et al. Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol 2012, 19:1139-1146.
54. Chen H., Ruiz P.D., McKimpson W.M., Novikov L., Kitsis R.N., Gamble M.J. MacroH2A1 and ATM play opposing roles in paracrine senescence and the senescence-associated secretory phenotype. Mol Cell 2015, 59:719-731.
55. Hu Y., Chopra V., Chopra R., Locascio J.J., Liao Z., Ding H., Zheng B., Matson W.R., Ferrante R.J., Rosas H.D., et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A 2011, 108:17141-17146.
56. Faast R., Thonglairoam V., Schulz T.C., Beall J., Wells J.R., Taylor H., Matthaei K., Rathjen P.D., Tremethick D.J., Lyons I. Histone variant H2A.Z is required for early mammalian development. Curr Biol 2001, 11:1183-1187.
57. van Daal A., Elgin S.C. A histone variant, H2AvD, is essential in Drosophila melanogaster. Mol Biol Cell 1992, 3:593-602.
58. Iouzalen N., Moreau J., Mechali M. H2A.ZI, a new variant histone expressed during Xenopus early development exhibits several distinct features from the core histone H2A. Nucleic Acids Res 1996, 24:3947-3952.
59. Liu X., Li B., Gorovsky Ma Essential and nonessential histone H2A variants in Tetrahymena thermophila. Mol Cell Biol 1996, 16:4305-4311.
60. Eirin-Lopez J.M., Gonzalez-Romero R., Dryhurst D., Ishibashi T., Ausio J. The evolutionary differentiation of two histone H2A.Z. variants in chordates (H2A.Z-1 and H2A.Z-2) is mediated by a stepwise mutation process that affects three amino acid residues. BMC Evol Biol 2009, 9:31.
61. Bonisch C., Schneider K., Punzeler S., Wiedemann S.M., Bielmeier C., Bocola M., Eberl H.C., Kuegel W., Neumann J., Kremmer E., et al. H2A.Z.2.2 is an alternatively spliced histone H2A.Z. variant that causes severe nucleosome destabilization. Nucleic Acids Res 2012, 40:5951-5964.
62. Svotelis A., Gevry N., Gaudreau L. Regulation of gene expression and cellular proliferation by histone H2A.Z. Biochem Cell Biol 2009, 87:179-188.
63. Billon P., Cote J. Precise deposition of histone H2A.Z in chromatin for genome expression and maintenance. Biochim Biophys Acta 2013, 1819:290-302.
64. Papamichos-Chronakis M., Watanabe S., Rando O.J., Peterson C.L. Global regulation of H2A.Z localization by the INO80 chromatin-remodeling enzyme is essential for genome integrity. Cell 2011, 144:200-213.
65. Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., Stoll I., Roy L., Reilly P.T., Mak T.W., et al. ANP32E is a histone chaperone that removes H2A.Z from chromatin. Nature 2014, 505:648-653.
66. Mao Z., Pan L., Wang W., Sun J., Shan S., Dong Q., Liang X., Dai L., Ding X., Chen S., et al. Anp32e, a higher eukaryotic histone chaperone directs preferential recognition for H2A.Z. Cell Res 2014, 24:389-399.
67. Vardabasso C., Gaspar-Maia A., Hasson D., Punzeler S., Valle-Garcia D., Straub T., Keilhauer E.C., Strub T., Dong J., Panda T., et al. Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol Cell 2015, 59:75-88.
68. Baptista T., Graca I., Sousa E.J., Oliveira A.I., Costa N.R., Costa-Pinheiro P., Amado F., Henrique R., Jeronimo C. Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget 2013, 4:1673-1685.
69. Kim K., Punj V., Choi J., Heo K., Kim J.M., Laird P.W., An W. Gene dysregulation by histone variant H2A.Z. in bladder cancer. Epigenetics Chromatin 2013, 6:34.
70. Hua S., Kallen C.B., Dhar R., Baquero M.T., Mason C.E., Russell B.A., Shah P.K., Liu J., Khramtsov A., Tretiakova M.S., et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z. associated with breast cancer progression. Mol Syst Biol 2008, 4:188.
71. Svotelis A., Gevry N., Grondin G., Gaudreau L. H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle 2010, 9:364-370.